Construction of NKG2D CAR-NK92 cells and its killing effect on multiple myeloma cells.
- Author:
Jing LONG
1
,
2
;
Rong ZHENG
3
;
Sishi YE
3
;
Shanwen KE
3
;
Deming DUAN
4
;
Cheng WEI
3
;
Jimin GAO
5
Author Information
1. School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou 325035
2. Department of Clinical Laboratory, Dujiangyan Traditional Chinese Medicine Hospital, Chengdu 611830, China.
3. School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou 325035, China.
4. School of Public Health, Southern Medical University, Guangzhou 510515, China.
5. School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou 325035, China. *Corresponding author, E-mail: jimingao@wmu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Humans;
Mice;
Animals;
Receptors, Chimeric Antigen/genetics*;
Interleukin-15;
NK Cell Lectin-Like Receptor Subfamily K/metabolism*;
Granzymes;
Cell Line, Tumor;
Multiple Myeloma/therapy*;
Perforin
- From:
Chinese Journal of Cellular and Molecular Immunology
2023;39(7):577-585
- CountryChina
- Language:Chinese
-
Abstract:
Objective This study aims to construct and identify the chimeric antigen receptor NK92 (CAR-NK92) cells targeting NKG2D ligand (NKG2DL) (secreting IL-15Ra-IL-15) and verify the killing activity of NKG2D CAR-NK92 cells against multiple myeloma cells. Methods The extracellular segment of NKG2D was employed to connect 4-1BB and CD3Z, as well as IL-15Ra-IL-15 sequence to obtain a CAR expression framework. The lentivirus was packaged and transduced into NK92 cells to obtain NKG2D CAR-NK92 cells. The proliferation of NKG2D CAR-NK92 cells was detected by CCK-8 assay, IL-15Ra secretion was detected by ELISA and killing efficiency was detected by lactate dehydrogenase (LDH) assay. The molecular markers of NKp30, NKp44, NKp46, the ratio of apoptotic cell population, CD107a, and the secretion level of granzyme B and perforin were detected using flow cytometry. In addition, the cytotoxic mechanism of NKG2D CAR-NK92 cells on the tumor was verified by measuring the degranulation ability. Moreover, after NKG2D antibody inhibited effector cells and histamine inhibited tumor cells, LDH assay was utilized to detect the effect on cell-killing efficiency. Finally, the multiple myeloma tumor xenograft model was constructed to verify its anti-tumor activity in vivo. Results Lentiviral transduction significantly increased NKG2D expression in NK92 cells. Compared with NK92 cells, the proliferation ability of NKG2D CAR-NK92 cells was weaker. The early apoptotic cell population of NKG2D CAR-NK92 cells was less, and NKG2D CAR-NK92 cells had stronger cytotoxicity to multiple myeloma cells. Additionally, IL-15Ra secretion could be detected in its culture supernatant. NKp44 protein expression in NKG2D CAR-NK92 cells was clearly increased, demonstrating an enhanced activation level. Inhibition test revealed that the cytotoxicity of CAR-NK92 cells to MHC-I chain-related protein A (MICA) and MICB-positive tumor cells was more dependent on the interaction between NKG2D CAR and NKG2DL. After stimulating NKG2D CAR-NK92 cells with tumor cells, granzyme B and perforin expression increased, and NK cells obviously upregulated CD107α. Furthermore, multiple myeloma tumor xenograft model revealed that the tumors of mice treated with NKG2D CAR-NK92 cells were significantly reduced, and the cell therapy did not sensibly affect the weight of the mice. Conclusion A type of CAR-NK92 cell targeting NKG2DL (secreting IL-15Ra-IL-15) is successfully constructed, indicating the effective killing of multiple myeloid cells.
